GLP-1 Peptide Atlas, by Delfa

← Trials/Trial dossier/NCT05173714

RecruitingPhase 2

Sit Less, Interact and Move More (SLIMM) 2 Study

Lead sponsor

Srinvasan Beddhu

Asset

Semaglutide

Oral · GLP-1 agonist

Listed sites

Recruiting sites

Enrollment

156

estimated

Study population

Chronic kidney disease

Key I/E criterion

•eGFR 20-60

Primary endpoint

•Average Change in Sedentary Duration at Months 8, 10 and 12 from Randomization

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT05173714

Org study ID138494

Secondary ID1R01DK128640-01

Timeline

Milestones

Study start2021-12-01actual

Study first posted2021-12-30actual

Last update posted2025-06-05actual

Primary completion2026-12-31estimated

Study completion2027-03-31estimated

Assets

Investigational agents

Semaglutide

Study populations

Who this study enrolls

Chronic kidney disease

Eligibility

Who can enroll

Minimum age20 Years

SexAll

Healthy volunteersNot accepted

Inclusion criteria

•Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) Glomerular Filtration Rate (eGFR) 20 to <60 mL/min/1.73m^2

•Able to perform resistance training

•Access to compatible "smartphone" or device (i.e., Android, Kindle or Apple with internet connectivity or mobile network), desktop or laptop

Exclusion criteria

•Type 1 Diabetes

•History of gastroparesis or paralytic ileus

•At baseline, if sedentary time is 25 min/hr or less, measured by accelerometer

•Potential contraindications to semaglutide such as a history of pancreatitis, and a family or personal history of multiple endocrine neoplasia type 2 or familial medullary thyroid carcinoma.

•Previous bariatric surgery

•Medical condition likely to limit survival to less than 1 year

•Anticipated start of dialysis or kidney transplantation within 6 months

•Any factors judged by the investigator or study team to likely limit adherence to interventions

•Vulnerable populations- pregnant or incarcerated

•Enrolled in interventional trials using drugs or devices

•Not able to undergo informed consent

•Recent hospitalizations or major interventional procedures done within the past 60 days

•Known or suspected hypersensitivity to tegaderm

•Use of any GLP-1 receptor agonist within 30 days prior to screening

•Presently classified as being in New York Heart Association (NYHA) Class IV Heart Failure

•Daytime use of supplemental oxygen (i.e., prescribed a stationary or portable oxygen system)

•Presence of metastatic cancer

•Current use of mobility aid(s)

•Living in the same household of a participant already enrolled in the study

Endpoints (11)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Other clinical outcomes

Patient-reported / QoL

Weight & body composition

Heart failure

Cardiometabolic biomarkers

Other (unclassified)

Weight & body composition

1 endpoint

Secondary/protocol endpoint

Average Change in Body Fat % at Months 6 and 12 from Randomization

Time frame:Randomization to 12 Months

change from baseline, improvement

Heart failure

1 endpoint

Secondary/protocol endpoint

Average Change in Six-Minute Walk at Months 6 and 12 from Randomization

Time frame:Randomization to 12 Months

6-minute walk distance

change from baseline, improvement

Cardiometabolic biomarkers

1 endpoint

Other/protocol endpoint/low confidence

Average Change in Circulating Protein Markers of Inflammation at Months 6 and 12 from Randomization

Time frame:Randomization to 12 Months

change from baseline, improvement

Patient-reported / QoL

3 endpoints

Other/protocol endpoint

Average Change in Patient Reported Fatigue at Months 6 and 12 from Randomization

Time frame:Randomization to 12 Months

change from baseline, improvement

Other/protocol endpoint

Average Change in Patient Reported Sleep at Months 6 and 12 from Randomization

Time frame:Randomization to 12 Months

change from baseline, improvement

Other/protocol endpoint

Average Change in Patient Reported Quality of Life at Months 6 and 12 from Randomization

Time frame:Randomization to 12 Months

change from baseline, improvement

Other clinical outcomes

4 endpoints

Primary/protocol endpoint/low confidence

Average Change in Sedentary Duration at Months 8, 10 and 12 from Randomization

Time frame:Randomization to 12 Months

change from baseline, improvement

Secondary/protocol endpoint

Average Change in Steps per Day at Months 8, 10 and 12 from Randomization

Time frame:Randomization to 12 Months

change from baseline, improvement

Secondary/protocol endpoint/low confidence

Average Change in Stepping Duration at Months 8, 10 and 12 from Randomization

Time frame:Randomization to 12 Months

change from baseline, improvement

Other/protocol endpoint

Average Change in Lower Extremity Performance Battery Composite Score (LEP-CS) at Months 6 and 12 from Randomization

Time frame:Randomization to 12 Months

change from baseline, improvement

Other (unclassified)

1 endpoint

Other/protocol endpoint/low confidence

Average Change in microRNA (miRNA) Markers of Inflammation at Months 6 and 12 from Randomization

Time frame:Randomization to 12 Months

change from baseline, improvement

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 1, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.